Relevant bibliographies by topics / Pharmaceutical biotechnology

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Pharmaceutical biotechnology'

Author: Grafiati
Published: 4 June 2021
Last updated: 28 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Pharmaceutical biotechnology.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Pharmaceutical biotechnology"

1

Boulay, Jean-Louis, and Sylvie Miot. "Chemical biotechnology Pharmaceutical biotechnology." Current Opinion in Biotechnology 11, no. 6 (December 2000): 515. http://dx.doi.org/10.1016/s0958-1669(00)00138-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Boulay, Jean-Louis. "Pharmaceutical biotechnology: Chemical biotechnology." Current Opinion in Biotechnology 10, no. 6 (December 1999): 523–24. http://dx.doi.org/10.1016/s0958-1669(99)00022-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Roque-Borda, Cesar Augusto, Fernando Rogério Pavan, and Andréía Bagliotti Meneguin. "Pharmaceutical Biotechnology." Life 12, no. 8 (August 16, 2022): 1240. http://dx.doi.org/10.3390/life12081240.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Lawn, Richard M., and Laurence A. Lasky. "Pharmaceutical biotechnology." Current Opinion in Biotechnology 11, no. 6 (December 2000): 579–80. http://dx.doi.org/10.1016/s0958-1669(00)00156-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

GUZMAN, C., and G. FEUERSTEIN. "Pharmaceutical biotechnology." Current Opinion in Biotechnology 15, no. 6 (December 2004): 503–5. http://dx.doi.org/10.1016/s0958-1669(04)00147-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Liu, D. "Pharmaceutical biotechnology." Current Opinion in Biotechnology 7, no. 6 (December 1996): 581–82. http://dx.doi.org/10.1016/s0958-1669(96)80067-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Knowles, Jonathan. "Pharmaceutical biotechnology." Current Opinion in Biotechnology 8, no. 6 (December 1997): 667–68. http://dx.doi.org/10.1016/s0958-1669(97)80116-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Olson, Eric R., and Barry Ratzkin. "Pharmaceutical biotechnology." Current Opinion in Biotechnology 10, no. 6 (December 1999): 525–27. http://dx.doi.org/10.1016/s0958-1669(99)00023-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Metcalf, Brian, and Rino Rappuoli. "Pharmaceutical biotechnology." Current Opinion in Biotechnology 14, no. 6 (December 2003): 618–20. http://dx.doi.org/10.1016/j.copbio.2003.10.008.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

McCormick, Frank, and Wendell Wierenga. "Pharmaceutical biotechnology." Current Opinion in Biotechnology 6, no. 6 (January 1995): 621–23. http://dx.doi.org/10.1016/0958-1669(95)80102-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Pharmaceutical biotechnology"

1

Ashton, Gabrielle Anne. "The impact of biotechnology on pharmaceutical R&D." Thesis, Cardiff University, 2001. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.273542.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Chen, Allen Kuan-Liang Biotechnology &amp Biomolecular Sciences Faculty of Science UNSW. "Enhanced biocatalyst production for (R)-phenylacetylcarbinol synthesis." Awarded by:University of New South Wales. School of Biotechnology and Biomolecular Sciences, 2006. http://handle.unsw.edu.au/1959.4/32825.

Full text
Abstract:
The enzymatic production of R-phenylacetylcarbinol (R-PAC), with either whole cells or partially purified pyruvate decarboxylase (PDC) as the biocatalyst, requires high PDC activity and an inexpensive source of pyruvate for an economical feasible biotransformation process. Microbial pyruvate produced by a vitamin auxotrophic strain of Candida glabrata was selected as a potential substrate for biotransformation. With an optimal thiamine concentration of 60 ??g/l, a pyruvic acid concentration of 43 g/l and yield of 0.42 g/g glucose consumed were obtained. Using microbially-produced unpurified pyruvate resulted in similar PAC concentrations to those with commercial pure substrate confirming its potential for enzymatic PAC production. To obtain high activity yeast PDC, Candida utilis was cultivated in a controlled bioreactor. Optimal conditions for PDC production were identified as: fermentative cell growth at initial pH at 6.0 followed by pH downshift to 3.0. Average specific PDC carboligase activity of 392 ?? 20 U/g DCW was achieved representing a 2.7-fold increase when compared to a constant pH process. A mechanism was proposed in which the cells adapted to the pH decrease by increasing PDC activity to convert the accumulated internal pyruvic acid via acetaldehyde to ethanol thereby reducing intracellular acidification. The effect of pH shift on specific PDC activity of Saccharomyces cerevisiae achieved a comparable increase of specific PDC carboligase activity to 335 U/g DCW. The effect of pyruvic acid at pH 3.0 on induction of PDC activity was confirmed by cultivation at pH 3 with added pyruvic acid. Using microarray techniques, genome-wide transcriptional analyses of the effect of pH shift on S. cerevisiae revealed a transient increased expression of PDC1 after pH shift, which corresponded to the increase in specific PDC activity (although the latter was sustained for a longer period). The results showed significant gene responses to the pH shift with approximately 39 % of the yeast genome involved. The induced transcriptional responses to the pH shift were distinctive and showed only limited resemblance to gene responses reported for other environmental stress conditions, namely increased temperature, oxidative conditions, reduced pH (succinic acid), alkaline pH and increased osmolarity.
APA, Harvard, Vancouver, ISO, and other styles
3

Hansen, Zeynep. "Contractual arrangements under technological uncertainty: Analysis of pharmaceutical and biotechnology collaborations." Diss., The University of Arizona, 2002. http://hdl.handle.net/10150/280007.

Full text
Abstract:
This dissertation investigates the conditions that shape the governance structure of contractual agreements and how different contract types address the potential problems that can arise in R&D partnerships under technological uncertainty. The motivation for this study arises from the emergence of new forms of R&D organization to cope with challenges as well as opportunities created by rapid technological change. This dissertation demonstrates the significance of technological uncertainty in determining the observed variety of contractual arrangements in the biotechnology industry. It also shows that the returns from collaborative arrangements as measured by the number of successful patents differ among various contract types. The first part of this research focuses on biotechnology alliances with pharmaceutical companies involving drug discovery research. It demonstrates how advances in technology affect the structure of R&D contracts. Using contractual data over time, it is shown that newer technologies associated with higher uncertainty result in the choice of more equity participation by the pharmaceutical partner and more hierarchical contractual arrangements. This result supports the transaction cost arguments that as contractual difficulties arise, allying firms are more likely to choose a more hierarchical governance form over simpler arrangements. The second part of the dissertation investigates the significance of external R&D investments by large pharmaceutical companies to their overall innovation process. The performance of collaborations on the overall R&D productivity are evaluated in terms of their impact on successful patent production. This study measures the innovative returns to R&D collaborations separate from in-house R&D resources and possible knowledge spillovers. Using a panel data set of large pharmaceutical companies, a knowledge production function is estimated. The results indicate that the implied long-run elasticity of successful patent output with respect to all active R&D alliances is lower than the elasticity estimate with respect to in-house R&D investments. In addition, marginal returns to R&D collaborations differ among various contractual types, in terms of their contribution to patent production process. It is also shown that knowledge spillovers by competitors contribute to patent production, but scientific publications hinder it.
APA, Harvard, Vancouver, ISO, and other styles
4

Smedsrud, Sabina, Simon Ekdahl, and Emil Näslund. "Optimising a launch : Important factors affecting a new pharmaceutical launch in Sweden." Thesis, Uppsala universitet, Industriell teknik, 2019. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-384677.

Full text
Abstract:
This master thesis explores the launch process of new pharmaceuticals in Sweden. The path of a pharmaceutical from idea to innovation is a long and arduous process with only few new products actually reaching the patients in the end. Seeing as the drug development is also an expensive process, it is of importance that the products that get approval meet their expected revenue. New pharmaceuticals can also be life changing for the patient, and thus it is important that once approval is received the patients gain access to the new treatments. This study focuses on the post regulatory approval processes in Sweden, as well as activities carried out by the companies that affect the adoption of a new product. By utilizing a qualitative study, this thesis aims to describe the internal and external factors that affect the pharmaceutical launch process in Sweden. As well as exploring what future initiatives and possible changes that might affect it. Ten interviews with different company representatives as well as six interviews with governmental and regional stakeholders were analysed using grounded theory to answer what factors affect the adoption of new pharmaceuticals. Factors that were found to be important were: Utilisation of cross-functional teams, clear and simple strategy that includes the whole organisation, communicating with national and regional authorities, and get feedback from these, communicate with patient representatives and organisations as well as developing utility services for the product. From a couple of these factors a trend towards the servicification of the pharmaceutical industry was discovered.
APA, Harvard, Vancouver, ISO, and other styles
5

Alimov, Azizjon. "Innovations, real options, risk and return : evidence from the pharmaceutical and biotechnology industries /." view abstract or download file of text, 2007. http://proquest.umi.com/pqdweb?did=1421619401&sid=1&Fmt=2&clientId=11238&RQT=309&VName=PQD.

Full text
Abstract:
Thesis (Ph. D.)--University of Oregon, 2007.
Typescript. Includes vita and abstract. Includes bibliographical references (leaves 109-114). Also available for download via the World Wide Web; free to University of Oregon users.
APA, Harvard, Vancouver, ISO, and other styles
6

Gunawan, Cindy Biotechnology &amp Biomolecular Sciences Faculty of Science UNSW. "Bioprocess development for (R)-phenylacetylcarbinol (PAC) synthesis in aqueous/organic two-phase system." Awarded by:University of New South Wales. School of Biotechnology and Biomolecular Sciences, 2006. http://handle.unsw.edu.au/1959.4/25711.

Full text
Abstract:
(R)-phenylacetylcarbinol or R-PAC is a chiral precursor for the synthesis of pharmaceuticals ephedrine and pseudoephedrine. PAC is produced through biotransformation of pyruvate and benzaldehyde catalyzed by pyruvate decarboxylase (PDC) enzyme. The present research project aims at characterizing a two-phase aqueous/organic process for enzymatic PAC production. In a comparative study of several selected yeast PDCs, the highest PAC formation was achieved in systems with relatively high benzaldehyde concentrations when using C. utilis PDC. C. tropicalis PDC was associated with the lowest by-product acetoin formation although it also produced lower PAC concentrations. C. utilis PDC was therefore selected as the biocatalyst for the development of the two-phase PAC production. From an enzyme stability study it was established that PDC deactivation rates in the twophase aqueous/octanol-benzaldehyde system were affected by: (1) soluble octanol and benzaldehyde in the aqueous phase, (2) agitation rate, (3) aqueous/organic interfacial area, and (4) initial enzyme concentration. PDC deactivation was less severe in the slowly stirred phase-separated system (low interfacial area) compared to the rapidly stirred emulsion system (high interfacial area), however the latter system was presumably associated with a faster rate of organic-aqueous benzaldehyde transfer. To find a balance between maintaining enzyme stability while enhancing PAC productivity, a two-phase system was designed to reduce the interfacial contact by decreasing the organic to aqueous phase volume ratio. Lowering the ratio from 1:1 to 0.43:1 resulted in increased overall PAC production at 4??C and 20??C (2.5 M MOPS, partially purified PDC) with a higher concentration at the higher temperature. The PAC was highly concentrated in the organic phase with 212 g/L at 0.43:1 in comparison to 111 g/L at 1:1 ratio at 20??C. The potential of further two-phase process simplification was evaluated by reducing the expensive MOPS concentration to 20 mM (pH controlled at 7.0) and employment of whole cell PDC. It was found that 20??C was the optimum temperature for PAC production in such a system, however under these conditions lowering the phase ratio resulted in decreased overall PAC production. Two-phase PAC production was relatively low in 20 mM MOPS compared to biotransformations in 2.5 M MOPS. Addition of 2.5 M dipropylene glycol (DPG) into the aqueous phase with 20 mM MOPS at 0.25:1 ratio and 20??C improved the production with organic phase containing 95 g/L PAC. Although the productivity was lower, the system may have the benefit of a reduction in production cost.
APA, Harvard, Vancouver, ISO, and other styles
7

Gretton, Linda Burak. "The rhetorical helix of the biotechnology and pharmaceutical industries strategies of transformation though definition, description and ingratiation /." Greensboro, N.C. : University of North Carolina at Greensboro, 2007. http://libres.uncg.edu/edocs/etd/1435/umi-uncg-1435.pdf.

Full text
Abstract:
Thesis (Ph.D.)--University of North Carolina at Greensboro, 2007.
Title from PDF t.p. (viewed Oct. 22, 2007). Directed by Nancy Myers; submitted to the Dept. of English. Includes bibliographical references (p. 209-228).
APA, Harvard, Vancouver, ISO, and other styles
8

Nel, Izak Bartholomeus Jacques. "The relationship between global pharmaceutical companies and the biotechnology industry in South Africa : implications for an emerging biotechnology industry in South Africa." Thesis, Stellenbosch : Stellenbosch University, 2003. http://hdl.handle.net/10019.1/53672.

Full text
Abstract:
Mini-study project (MBA)--University of Stellenbosch, 2003.
ENGLISH ABSTRACT: This report reviews the global and South African pharmaceutical and biotechnology industries and provides an overview of the changes taking place within these two industries. It highlights the impact this relationship will have on a developing South African biotechnology industry. Since the 1980s the pharmaceutical industry has experienced phenomenal growth in sales and profits. By the mid 1990s drug sales exceeded USD250 billion. Today the pharmaceutical industry is dominated by multi-national corporations with extensive R&D budgets, widespread use of trademarks and patents and complex commercial process technology. However they face threats from depleted product pipelines, patent expiry on billion dollar drug products, generic competition, increases in drug approval times, costs and price pressures. The entrepreneurial biotechnology industry promises to solve a number of the pharmaceutical industry's problems. In recent years biotechnology companies proved more effective in the development of new molecular entities. They promise individualised therapeutics, novel and more efficacious drug discovery and development of preventative treatments. However the decrease in equity financing after 2001 left almost 40% of biotechnology companies with less than 1 year of R&D funding. The industry experienced losses again in 2002 and the world is divided over the ethical, environmental and economic implications of biotechnological applications. The biotechnology and pharmaceutical industries have a symbiotic but antagonistic relationship. The change in this relationship will hugely affect South Africa's ideals of developing a biotechnology industry. Various diseases plague South Africa including HIV/AIDS, TB, obesity, diabetes, hypertension and infective diseases. These diseases will have a huge impact on South Africa's society. Yet only 10% of global R&D funding is committed to third world diseases and existing drugs and treatments are either not effective or too expensive for developing countries. It is in this situation that biotechnology and the development of a biotechnology industry could playa major role in alleviating South Africa's health burden. South Africa is already capable in first generation biotechnology, but third generation applications holds the most promise. Developing countries face various obstacles and challenges, but all boast well for South Africa. The government has committed R400 million (over a three year period) to utilize South Africa's biotechnology potential. Further, the country has highly skilled researchers, indigenous plant and animal species, a diverse population and a favorable exchange rate (low R&D costs).
AFRIKAANSE OPSOMMING: Die projek ondersoek beide die globale en Suid Afrikaanse farmaseutiese en biotegnologie industrieë. Verder word die veranderinge wat plaasvind in die industrieë onder die soeklig geplaas. Die projek beklemtoon die impak wat die verhouding sal hê op 'n ontwikkelende biotegnologie industrie in Suid Afrika. Die farmaseutiese industrie het sedert die 1980s dubbel syfer groei getoon in omsete en wins. Teen die middel 90's het verkope van farmaseutiese middels US$250 miljard wêreldwyd oorskry. Vandag word die farmaseutiese industrie oorheers deur multi-nasionale korporasies met omvattende navorsing en ontwikkelings begrotings, algemene gebruik van handelsmerkte, patente en komplekse proses-tegnologieë. Ten spyte hiervan word die industrie bedreig deur leë produksie-lyne, verval van patente, miljard dollar farmaseutiese produkte, generiese kompetisie, verlengde produk-goedkeurings periodes en prys-mededinging. Die biotegnologie industrie met sy innoveerende eienskappe beloof om verskeie van die farmaseutiese industrie se probleme op te los. Onlangs het biotegnologie maatskappye getoon dat hulle meer effektief is in die ontwikkeling van nuwe molekulêre eenhede. Biotegnologie beloof nuwe en meer effektiewe produk-ontwikkeling asook beter individuele terapieë en voorkomende behandelings. Die industrie staar finansiële krisisse in die gesig. Slegs 40% van biotegnologie maatskappye het voldoende navorsing en ontwikkelings-kapitaal tot 2004. Dit is hoofsaaklik as gevolg van 'n afname in eienaars-finansiering na 2001. Die industrie as 'n geheel het weereens 'n verlies gelei in 2002 en die wêreld is verdeeld oor die etiese, omgewings en ekonomiese implikasie van biotegnologiese toepassings. Die biotegnologie en farmaseutiese industrieë het 'n simbiotiese maar tog vyandige verhouding. 'n Verandering in die verhouding gaan Suid Afrika se ideale om 'n biotegnologie industrie te skep grootliks beïnvloed. Suid Afrika gaan gebuk onder verskeie siektes insluitende MIVNIGS, TB, vetsugtigheid, diabetes, hipertensie en infeksie siektes. Hierdie siektes het 'n groot impak op Suid Afrika se samelewing. Tog word slegs 10% van die globale navorsings en ontwikkelingsfondse aangewend om 'n oplossing te vind vir derdewêreld siektes. Verder is bestaande produkte en behandelings oneffektief of onbekostigbaar vir ontwikkelde lande. Dit is in sulke gevalle waar biotegnologie en die ontwikkeling van 'n biotegnologie industrie 'n groot rol kan speel in die verligting van Suid Afrika se gesondheids-las. Suid Afrika is vaardig in eerste-generasie biotegnologie, maar wêreld wyd hou derde generasie biotegnologie die meeste belofte in. Die tegnologie is tot op hede onderbenut in Suid Afrika. Ontwikkelende lande staar verskeie uitdagings in die gesig, maar Suid Afrika het talle sterk punte. Die regering het R400 miljoen (oor 'n drie jaar periode) beskikbaar gestel vir die ontwikkeling van Suid Afrika se biotegnologie potensiaal. Die land beskik ook oor navorsers van hoogstande gehalte, onbenutte inheemse plante en dier spesies, 'n diverse populasie en 'n gunstige wisselkoers (lae navorsings en ontwikkelings kostes).
APA, Harvard, Vancouver, ISO, and other styles
9

Vazquez, Toro Guillermo J. "Patent Quality And Company Performance| A Sample within the USA Biotechnology and Pharmaceutical Industry." Thesis, Inter-American University of Puerto Rico (Puerto Rico), 2014. http://pqdtopen.proquest.com/#viewpdf?dispub=3577982.

Full text
Abstract:

This Dissertation investigates the relationship between patent quality and company performance for a sample from the US Biotechnology and Pharmaceutical Industry. The methodology devised comprehensively examines patent worth (patent’s references), patent protection (claims and family patents) and patent quality (references, claims and family patents) to determine their implications on firm leverage (SE, TA), profits (ROE, ROA), and market value (B/M, MCap). The selected sample comprises 1,536 companies, and 285,000 patents from 1999 to 2009. The results show that total revenue just responds to changes in R&D; intensity, and patenting intensity. A 10 percent increase in patent value results in a corresponding increase rate on the market capitalization index for the full sample and a 14 percent increase for the chemicals and allied products group (SIC 28). Increases (10%) in patent protection and quality present average increases of 15 percent on market capitalization for the full sample and 8 percent for the chemicals and allied products group (SIC 28). The medical devices group (SIC 38) results suggest that Mcap increases 10 percent by the same increase in patent value index. Patent protection and quality increases (10%) suggest an average 8 percent increase in Mcap. Results suggest that profits, leverage and market indices respond differently to 10 percent increases in patent value, patent protections and patent quality. The aforementioned effects suggest that the qualitative indexes follow company related market activities and business valuations for the chemical and allied products, and medical devices industrial sectors.

APA, Harvard, Vancouver, ISO, and other styles
10

Pavúk, Šimon. "Aplikácia investičnej analýzy na biotechnologicko- farmaceutický sektor." Master's thesis, Vysoká škola ekonomická v Praze, 2010. http://www.nusl.cz/ntk/nusl-76239.

Full text
Abstract:
The principal aim of this thesis is to describe methods of fundamental analysis of three major companies from sectors of Biotechnology and Pharmaceuticals, namely Johnson & Johnson, Pfizer and Amgen. Among used methods we are able to find 2 -- stage discounted cashlow models Free-cashflow-to-equity FCFE and Free-cashflow-to-firm FCFF, Gordon's dividend discount model a relative valuation methods using P/E, P/BV and P/S. Descriptive part of this thesis describes legal and regulatory environment, which has significant impact on the development process of new innovative drugs and therapies. Further it sets investment recommendations and looks closer at investment opportunities in biotechnological companies.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Pharmaceutical biotechnology"

1

Crommelin, Daan J. A., Robert D. Sindelar, and Bernd Meibohm, eds. Pharmaceutical Biotechnology. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-00710-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Kayser, Oliver, and Heribert Warzecha, eds. Pharmaceutical Biotechnology. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA, 2012. http://dx.doi.org/10.1002/9783527632909.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Crommelin, Daan J. A., Robert D. Sindelar, and Bernd Meibohm, eds. Pharmaceutical Biotechnology. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-6486-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Guzmán, Carlos A., and Giora Z. Feuerstein, eds. Pharmaceutical Biotechnology. New York, NY: Springer New York, 2009. http://dx.doi.org/10.1007/978-1-4419-1132-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Crommelin, Daan J. A., Robert D. Sindelar, and Bernd Meibohm, eds. Pharmaceutical Biotechnology. Cham: Springer International Publishing, 2024. http://dx.doi.org/10.1007/978-3-031-30023-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

J, Groves M., ed. Pharmaceutical biotechnology. 2nd ed. Boca Raton, FL: Taylor&Francis, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

1959-, Guzman Carlos Alberto, and Feuerstein Giora Z. 1946-, eds. Pharmaceutical biotechnology. New York: Springer Science+Business Media, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Ashutosh, Kar, and ebrary Inc, eds. Pharmaceutical biotechnology. New Delhi: New Age International (P) Ltd., Publishers, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Klefenz, Heinrich. Industrial pharmaceutical biotechnology. Weinheim: Wiley-VCH, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

A, Crommelin D. J., and Sindelar Robert D, eds. Pharmaceutical biotechnology: An introduction for pharmacists and pharmaceutical scientists. Amsterdam, The Netherlands: Harwood Academic Publishers, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Pharmaceutical biotechnology"

1

Brunn, Gregory J., and Jeffrey L. Platt. "Xenotransplantation in Pharmaceutical Biotechnology." In Pharmaceutical Biotechnology, 581–97. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA, 2012. http://dx.doi.org/10.1002/9783527632909.ch22.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Brunn, Gregory J., and Jeffrey L. Platt. "Xenotransplanation in Pharmaceutical Biotechnology." In Pharmaceutical Biotechnology, 265–79. Weinheim, FRG: Wiley-VCH Verlag GmbH & Co. KGaA, 2005. http://dx.doi.org/10.1002/3527602410.ch15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Kolassa, Eugene M., and Tushar B. Padwal. "Economic Considerations in Medical Biotechnology." In Pharmaceutical Biotechnology, 237–45. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-6486-0_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Patel, Amit S., and Kartick P. Shirur. "Economic Considerations in Medical Biotechnology." In Pharmaceutical Biotechnology, 253–63. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-00710-2_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Patel, Amit S., and Kartick P. Shirur. "Economic Considerations in Medical Biotechnology." In Pharmaceutical Biotechnology, 255–65. Cham: Springer International Publishing, 2024. http://dx.doi.org/10.1007/978-3-031-30023-3_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Borchardt, Ronald T., Philip L. Smith, and Glynn Wilson. "General Principles in the Characterization and Use of Model Systems for Biopharmaceutical Studies." In Pharmaceutical Biotechnology, 1–11. Boston, MA: Springer US, 1996. http://dx.doi.org/10.1007/978-1-4899-1863-5_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Brouwer, Kim L. R., and Ronald G. Thurman. "Isolated Perfused Liver." In Pharmaceutical Biotechnology, 161–92. Boston, MA: Springer US, 1996. http://dx.doi.org/10.1007/978-1-4899-1863-5_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Gutierrez, Marcelo M., Claire M. Brett, and Kathleen M. Giacomini. "Isolated Renal Brush Border and Basolateral Membrane Vesicles and Cultured Renal Cells." In Pharmaceutical Biotechnology, 193–210. Boston, MA: Springer US, 1996. http://dx.doi.org/10.1007/978-1-4899-1863-5_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Okudaira, Noriko, and Yuichi Sugiyama. "Use of an Isolated Perfused Kidney to Assess Renal Clearance of Drugs." In Pharmaceutical Biotechnology, 211–38. Boston, MA: Springer US, 1996. http://dx.doi.org/10.1007/978-1-4899-1863-5_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Audus, Kenneth L., Lawrence Ng, Wen Wang, and Ronald T. Borchardt. "Brain Microvessel Endothelial Cell Culture Systems." In Pharmaceutical Biotechnology, 239–58. Boston, MA: Springer US, 1996. http://dx.doi.org/10.1007/978-1-4899-1863-5_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Pharmaceutical biotechnology"

1

Akchurin, Sergey V., Ekaterina S. Krasnikova, Georgy P. Dulger, Irina V. Akchurina, Alexandr V. Krasnikov, Evgenia S. Latynina, and Vladislav S. Bychkov. "Ecological aspects of pharmaceutical biotechnology." In VII INTERNATIONAL CONFERENCE “SAFETY PROBLEMS OF CIVIL ENGINEERING CRITICAL INFRASTRUCTURES” (SPCECI2021). AIP Publishing, 2023. http://dx.doi.org/10.1063/5.0126350.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Gholoom, Sheikha Ishaq Abdallah, and Panagiotis D. Zervopoulos. "The Effect of Mergers and Acquisitions on Efficiency: Evidence from the Pharmaceutical Industry." In International Symposium on Engineering and Business Administration. Switzerland: Trans Tech Publications Ltd, 2023. http://dx.doi.org/10.4028/p-qlbab6.

Full text
Abstract:
This study emphasizes the assessment of efficiency and the degree of operating efficiency of mergers and acquisitions in the pharmaceutical industry worldwide. This industry encounters various challenges such as expiring patents, the rise of genetics pharmaceuticals, the entrance of biotechnology companies in the pharmaceutical market, the increasing research and development expenses, government regulations of the pharmaceutical industry, distribution channels, and drug prices. All these challenges result in an intensely competitive environment in which pharmaceuticals suffering from shortcomings (e.g., operational and/or financial inefficiencies) are not easy to catch up with the competition. Mergers and acquisitions are major activities to overcome shortcomings and achieve growth. Mergers and acquisitions have been widely used in the pharmaceutical industry for many years and are expected to accelerate. The objective of this work is to identify whether mergers and acquisitions between pharmaceutical companies can be successful and to highlight the most favourable consolidations. The assessment of mergers and acquisitions is realized through conventional and stochastic data envelopment analysis approaches. The empirical analysis draws on a sample of 371 pharmaceutical companies. The original sample was extended by 870 possible combinations between firms. Our empirical analysis reveals a positive impact of mergers and acquisitions on the efficiency of pharmaceutical companies.
APA, Harvard, Vancouver, ISO, and other styles
3

Bhushan, Indu. "Efficient media for high production of microbial lipase from Bacillus subtilis (BSK-L) using response surface methodology for enantiopure synthesis of drug molecules." In 2nd International Scientific Conference "Plants and Microbes: the Future of Biotechnology". PLAMIC2020 Organizing committee, 2020. http://dx.doi.org/10.28983/plamic2020.044.

Full text
Abstract:
Lipases are a multipurpose enzyme that holds a significant position in industrial applications due to its ability to catalyse a large number of reactions such as hydrolysis, esterification, interesterification, transesterification which makes it a potential candidate. It is also used for the separation of chiral drugs from the racemic mixture and this property of lipase is considered very important in pharmaceutical industries for the synthesis of enantiopure bioactive molecules. Assuming the tremendous importance of lipases, as stereoselective biocatalysts, in pharmaceuticals and various other commercial applications, industrial enzymologists have been forced to search for those microorganisms which are able to produce novel biocatalysts at reasonably high yield. In the present study microbial lipase was isolated from the water sample of pond at Katra, Jammu and Kashmir (India). This enzyme has shown wide specificity and higher enantioselectivity, which make it pharmaceutical important enzyme. To make it economical for industrial application, it was produced on cheap nutrient media using Response Surface Methodology and got maximum production. It was used for resolution of chiral drugs and the significant results obtained during the course of work shall have potential towards pharmaceutical industries.
APA, Harvard, Vancouver, ISO, and other styles
4

Shammout, Hadi, Tamás Sovány, and Krisztina Ludasi. "Laser applications in pharmaceutical industry." In V. Symposium of Young Researchers on Pharmaceutical Technology,Biotechnology and Regulatory Science. Szeged: Institute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, Faculty of Pharmacy, 2023. http://dx.doi.org/10.14232/syrptbrs.2023.61.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

MATOS, Murilo Montanari de, and Sérgio Robles Reis de QUEIROZ. "Technical Change and the Incorporation of Biotechnology in the Pharmaceutical Industry." In II Encontro Nacional de Economia Industrial e Inovação. São Paulo: Editora Blucher, 2017. http://dx.doi.org/10.5151/enei2017-06.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Shammout, Hadi, Bence Sipos, Krisztina Ludasi, Selenay Belge, and Tamás Sovány. "Coating technology in the pharmaceutical industry." In VI. Symposium of Young Researchers on Pharmaceutical Technology,Biotechnology and Regulatory Science. Szeged: Institute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, Faculty of Pharmacy, 2024. http://dx.doi.org/10.14232/syrptbrs.2024.42.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Mroz, Kamil, and Olivier Lisein. "PROJECT MANAGEMENT IN THE PHARMACEUTICAL AND BIOTECHNOLOGY SECTORS: EVOLUTION & FUTURE RESEARCH OPPORTUNITIES." In 10th IPMA Research conference: Value co-creation in the project society. International Project Management Association, Serbian Project Management Association, 2022. http://dx.doi.org/10.56889/gyug4635.

Full text
Abstract:
This paper seeks to investigate the main areas of academic research in project management as they relate to the pharmaceutical and biotechnology sector, and specifically how research on project management in this sector has evolved over the period 1990 – 2021. Leveraging a Systematic Literature Review, this paper analyzes academic works to determine areas of insight, future research and key findings through grouping of the results into clusters aligned to the Star Model™ to better understand and to explore the evolution in key research areas, while exploring how and why did the emphasis change from 1990-2021. The implications for academia is that this sector is of particular interest in light of the COVID-19 pandemic where pharmaceutical and biotechnology companies took center stage overcoming traditional limitations to drug development, which included re-thinking traditional project management practices. A valuable contribution of this paper is made by pointing out the key research gaps to position opportunities for the formulation of pragmatic, contextualized ways forward and future research.
APA, Harvard, Vancouver, ISO, and other styles
8

Crișan, Andrea-Gabriela, Alina Porfire, Sonia Iurian, Tibor Casian, Lucia Rus, and Ioan Tomuță. "The broadening horizons of pharmaceutical 3D printing." In V. Symposium of Young Researchers on Pharmaceutical Technology,Biotechnology and Regulatory Science. Szeged: Institute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, Faculty of Pharmacy, 2023. http://dx.doi.org/10.14232/syrptbrs.2023.45.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Ahmed, Yusra, and Tamás Sovány. "Fused deposition modelling (FDM) in pharmaceutical technology." In VI. Symposium of Young Researchers on Pharmaceutical Technology,Biotechnology and Regulatory Science. Szeged: Institute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, Faculty of Pharmacy, 2024. http://dx.doi.org/10.14232/syrptbrs.2024.52.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Semnani Jazani, Reza, Zsófia Németh, Dorina Gabriella Dobó, and Ildikó Csóka. "Pharmaceutical study of essential oil-loaded liposomal formulations." In IV. Symposium of Young Researchers on Pharmaceutical Technology,Biotechnology and Regulatory Science. Szeged: Institute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, Faculty of Pharmacy, 2022. http://dx.doi.org/10.14232/syrptbrs.2022.59.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Pharmaceutical biotechnology"

1

Danzon, Patricia, Sean Nicholson, and Nuno Sousa Pereira. Productivity in Pharmaceutical Biotechnology R&D: The Role of Experience and Alliances. Cambridge, MA: National Bureau of Economic Research, April 2003. http://dx.doi.org/10.3386/w9615.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Hyman, Cody, Henry Dao, Gregory Vaughan, and Fred D. Ledley. Implications of the Inflation Reduction Act for the biotechnology industry; sensitivity of investment and valuation to drug price indices and market conditions. Institute for New Economic Thinking Working Paper Series, June 2024. http://dx.doi.org/10.36687/inetwp223.

Full text
Abstract:
The Inflation Reduction Act of 2022 contains landmark provisions authorizing the government to negotiate the price of selected drugs covered by Medicare Part D. The biopharmaceutical industry has criticized these provisions as a threat to innovation arguing that reducing future revenues could disincentivize equity investment in biotechnology. This research examines the sensitivity of private and public equity investment in the biotechnology industry to drug price indices and market conditions from 2000-2022. The analysis shows that equity financing and valuation in the biotechnology industry were strongly associated with equity market conditions but not indices of either producer or consumer drug prices. These results do not support claims of an association between changing drug prices and the availability of equity capital to emerging biotechnology companies, which currently sponsor the majority of all clinical trials. These results add to evidence that the IRA may not have a negative impact on pharmaceutical innovation.
APA, Harvard, Vancouver, ISO, and other styles
3

Greene, Anne, Kelly Waldron, and Nuala Calnan. Quality Risk Management: State of the Industry—Part 1. Has the Industry Realized the Full Value of ICH Q9? Institute of Validation Technology, January 2014. http://dx.doi.org/10.1080/21507090.ar1152014agkwnc-qrmsoi.

Full text
Abstract:
This paper summarizes research designed to characterize the current state of pharmaceutical and biotechnology industries with respect to the adoption of Quality Risk Management as per ICH Q9. The research supports the hypotheses that the full value of QRM with respect to product quality and patient safety has not yet been realized. In addition, industry appears to be lagging behind regulatory expectations with respect to QRM maturity, indicating that current approaches to QRM require significant improvement.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Pharmaceutical biotechnology' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography